The therapeutic effect of verapamil and triamcinolone along with macroneedling in the treatment of Peyronie's plaque

Comparison of the therapeutic effect of verapamil and triamcinolone drugs and their simultaneous use with macroneedling in patients with Peyronie's plaque

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230408057854N1

Enrollment

Registered

2023-05-11

Start date

2023-05-22

Completion date

Unknown

Last updated

2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peyronie's plaque. Peyronie's disease

Interventions

Intervention 1: Intervention group: use of macroneedling. Intervention 2: Control group: Treatment with triamcinolone and verapamil.

Eligibility

Sex/Gender

Male

Age

20 Years to 65 Years

Inclusion criteria

Inclusion criteria: Suffering from Peyronie's plaque confirmed by ultrasound Age between 20-65 years

Exclusion criteria

Exclusion criteria: History of trauma and penis fracture History of previous surgery on the penis History of pelvic radiotherapy

Design outcomes

Primary

Measure	Time frame
Peyronie's Plaque size. Timepoint: 6 weeks after the start of treatment. Method of measurement: By Penile ultrasound.	—

Secondary

Measure	Time frame
The amount of curvature of the penis. Timepoint: 6 weeks after the start of treatment. Method of measurement: Objective measurement by ruler.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHossein Rahnama

Shahid Beheshti University of Medical Sciences

rahnama2010@gmail.com+98 21 2271 8002

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026